“Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.”, Blood, vol. 135, no. 2, pp. 97-107, 2020.
, “Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.”, N Engl J Med, vol. 382, no. 20, pp. 1906-1915, 2020.
, “Remdesivir for the Treatment of Covid-19 - Preliminary Report.”, N Engl J Med, 2020.
, , ,
“Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.”, Vaccine, vol. 36, no. 5, pp. 606-614, 2018.
, “A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Utility of Tacrolimus (FK506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy.”, J Sex Med, vol. 15, no. 9, pp. 1293-1299, 2018.
, “A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation.”, Transpl Infect Dis, vol. 20, no. 3, p. e12874, 2018.
, “Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women.”, Vaccine, vol. 36, no. 31, pp. 4663-4671, 2018.
, “Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.”, Blood, vol. 132, no. 13, pp. 1438-1451, 2018.
, “Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.”, J Am Coll Cardiol, vol. 69, no. 5, pp. 526-537, 2017.
, “A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.”, Drug Alcohol Depend, vol. 177, pp. 249-257, 2017.
, “Recruiting a representative sample in adherence research-The MALT multisite prospective cohort study experience.”, Pediatr Transplant, vol. 21, no. 8, 2017.
, , “A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy.”, J Allergy Clin Immunol, vol. 137, no. 4, pp. 1103-1110.e11, 2016.
, “Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Networ”, Biol Blood Marrow Transplant, vol. 22, no. 8, pp. 1440-1448, 2016.
, “Retrospective Studies: A Fresh Look.”, Am J Speech Lang Pathol, vol. 25, no. 2, pp. 157-63, 2016.
, “A Randomized 36-Week Crossover Trial Comparing Ranibizumab and Bevacizumab for Diabetic Macular Edema”, in 2015 Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO), Denver, CO, 2015.
, “Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).”, Biol Blood Marrow Transplant, vol. 21, no. 1, pp. 4-7, 2015.
, “Rheumatologist Care in Rheumatoid Arthritis: Are We Dropping the Ball?”, in Canadian Rheumatology Association-Arthritis Health Professions Association Annual Scientific Meeting, Quebec, Canada, 2015.
, “Race and Ethnicity Differences in a MI-Based Brief Intervention Delivered in an ED Setting”, in College on Problems of Drug Dependence Meeting, San Juan, Puerto Rico, 2014.
, “Racial/Ethnic Differences in Clinical Trial Enrollment, Refusal Rates, Ineligibility, and Reasons for Decline Among Patients at Sites in The National Cancer Institute's Community Cancer Centers Program”, Cancer, vol. 120, pp. 877-884, 2014.
, “Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program.”, Cancer, vol. 120, no. 6, pp. 877-84, 2014.
, “Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome After Allogeneic Stem Cell Transplantation: BMT CTN Protocol”, Biol Blood Marrow Transplant, vol. 20, pp. 858-864, 2014.
, “Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials ne”, Biol Blood Marrow Transplant, vol. 20, no. 6, pp. 858-64, 2014.
,